Amgen Inc. (AMGN)
Why Amgen Stock Is Dropping After Swiss Rival's Trial Setback
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Amgen Touches 52-Week High: Buy, Sell or Hold the Stock?
AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pricing pressure and valuation warrant caution.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
Here's Why Amgen (AMGN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Safe High-Yield Stocks Boomers Should Own in August
Baby Boomers building retirement income want two things from a dividend stock: a check that shows up on schedule, and a balance sheet that says the check will still show up ten years from now.
Amgen: The Market Is Underestimating Its Next Growth Phase
The market has finally noticed Amgen's R&D achievements and progress in commercializing its key blockbusters in the treatment of cardiovascular diseases and IMIDs. So, sales of Tezspire, used to treat asthma and CRSwNP, rose 42.1% year-over-year to $486 million in the second quarter. On the other hand, Repatha, a PCSK9 inhibitor, generated $953 million in revenue for Amgen, up 8.8% quarter-on-quarter.
